{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.87","value":"0.4"},{"groupId":"OG001","spread":"0.99","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"title":"Mouth and Throat Soreness, Week 4 (n=202,180)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.88","value":"0.4"},{"groupId":"OG001","spread":"0.99","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"title":"Mouth and Throat Soreness, Week 10 (n=164,155)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.73","value":"0.3"},{"groupId":"OG001","spread":"0.89","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Mouth and Throat Soreness, Week 16 (n=137,138)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.75","value":"0.2"},{"groupId":"OG001","spread":"0.81","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"title":"Mouth and Throat Soreness, Week 22 (n=120,117)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"0.2"},{"groupId":"OG001","spread":"0.72","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"title":"Hand Soreness, Week 4 (n=200,184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.84","value":"0.3"},{"groupId":"OG001","spread":"0.85","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"Hand Soreness, Week 10 (n=164,153)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.76","value":"0.4"},{"groupId":"OG001","spread":"0.80","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"title":"Hand Soreness, Week 16 (n=139,136)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.69","value":"0.3"},{"groupId":"OG001","spread":"0.82","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"title":"Hand Soreness, Week 22 (n=123,115)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.86","value":"0.2"},{"groupId":"OG001","spread":"0.80","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"182"}],"units":"Participants"}],"title":"Foot Soreness, Week 4 (n=199,182)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.00","value":"0.3"},{"groupId":"OG001","spread":"0.99","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"Foot Soreness, Week 10 (n=163,153)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.07","value":"0.3"},{"groupId":"OG001","spread":"0.99","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"title":"Foot Soreness, Week 16 (n=140,136)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.04","value":"0.3"},{"groupId":"OG001","spread":"0.96","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Foot Soreness, Week 22 (n=123,116)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"The SQLQ scale consists of 5 items that assess the worst mouth and throat, hand, and foot soreness, as well as limitations due to mouth/throat and foot soreness. Participants were asked to assess their worst mouth/throat, hand, and foot soreness by answering the question of \" In the past 4 weeks, what was your worst mouth/throat, hand, and foot soreness?\" by using the following 4-point scale: 0, I never had any soreness; 1, I had a little bit of soreness; 2, I had quite a lot of soreness; 3, I had severe soreness. A positive mean change from Baseline represents a worsening of condition.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Some participants were missing scores at Baseline and were excluded from the analysis. Participants missing scores at other early time points were excluded from the analysis at those time points. Change from Baseline was calculated as the assessment week value minus the Baseline value.","reportingStatus":"POSTED","timeFrame":"Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Change From Baseline in the Supplementary Quality of Life Questions (SQLQ) Scale Worst Soreness Scores at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}